Use of BioSense for Rapid Assessment of the Safety of Medical Countermeasures

Description: 

BioSense is a national human health surveillance system for disease detection, monitoring, and situation awareness through near realtime access to existing electronic healthcare encounter information, including information from hospital emergency departments (EDs). MCM include antibiotics, antivirals, antidotes, antitoxins, vaccinations, nuclide-binding agents, and other medications. Although some MCM have been extensively evaluated and have FDA approval, many do not (1). Current FDA and CDC systems that monitor drug and vaccine safety have limited ability to monitor MCM safety, and in particular to conduct rapid assessments during an emergency.

Objective

To conduct an initial examination of the potential use of BioSense data to monitor and rapidly assess the safety of medical countermeasures (MCM) used for prevention or treatment of adverse health effects of biological, chemical, and radiation exposures during a public health emergency.

Primary Topic Areas: 
Original Publication Year: 
2012
Event/Publication Date: 
December, 2012

July 06, 2018

Contact Us

National Syndromic
Surveillance Program

Email:nssp@cdc.gov

The National Syndromic Surveillance Program (NSSP) is a collaboration among states and public health jurisdictions that contribute data to the BioSense Platform, public health practitioners who use local syndromic surveillance systems, Center for Disease Control and Prevention programs, other federal agencies, partner organizations, hospitals, healthcare professionals, and academic institutions.

Site created by Fusani Applications